Delayed
Nasdaq
01:57:10 2024-04-29 pm EDT
5-day change
1st Jan Change
1.42
USD
+4.41%
-4.05%
-35.16%
Presentation Operator MessageOperator (Operator)Good day, and welcome to the Aethlon Medical F...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Aethlon Medical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
Feb. 14
CI
Transcript : Aethlon Medical, Inc., Q3 2024 Earnings Call, Feb 14, 2024
Feb. 14
Transcript : Aethlon Medical, Inc., Q2 2024 Earnings Call, Nov 14, 2023
Nov. 14
Aethlon Medical, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
Nov. 14
CI
Aethlon Medical, Inc Announces Executive Changes
Nov. 13
CI
Aethlon Medical, Inc. Announces Appointment Ofguy Ciprian as Chief Operating Officer
Nov. 13
CI
HC Wainwright Adjusts Price Target on Aethlon Medical to $23 From $90, Maintains Buy Rating
23-10-24
MT
Aethlon Medical, Inc. Receives Clearance from Drug Controller General of India for Potential Phase 1 Trial of its Hemopurifier(R) in Oncology
23-10-10
CI
Aethlon Medical Board Approves 1-for-10 Reverse Stock Split
23-10-04
MT
Transcript : Aethlon Medical, Inc., Q1 2024 Earnings Call, Aug 10, 2023
23-08-10
Aethlon Medical, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023
23-08-10
CI
Aethlon Medical, Inc. Appoints Nicolas Gikakis as Member of the Board and Member of the Nominating Committee
23-07-06
CI
Transcript : Aethlon Medical, Inc., Q4 2023 Earnings Call, Jun 28, 2023
23-06-28
Aethlon Medical, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023
23-06-28
CI
Transcript : Aethlon Medical, Inc., Q3 2023 Earnings Call, Feb 13, 2023
23-02-13
Aethlon Medical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
23-02-13
CI
Aethlon Medical Taps Namsa to Manage Planned Clinical Trial of Medical Device for Cancer
23-01-30
MT
North American Morning Briefing : Stock Futures -2-
22-11-16
DJ
Maxim Downgrades Aethlon Medical to Hold From Buy
22-11-15
MT
Transcript : Aethlon Medical, Inc., Q2 2023 Earnings Call, Nov 14, 2022
22-11-14
Aethlon Medical, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022
22-11-14
CI
Aethlon Medical, Inc. Announces Early Feasibility Study of the Hemopurifier
22-09-29
CI
Transcript : Aethlon Medical, Inc. - Shareholder/Analyst Call
22-09-15
Aethlon Medical, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022
22-08-09
CI
Transcript : Aethlon Medical, Inc., Q1 2023 Earnings Call, Aug 09, 2022
22-08-09
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Aethlon Medical, Inc. (Aethlon) is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections suppression, seed the spread of metastasis and inhibit the benefit of cancer therapies. The Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression. Hemopurifier helps to bind and clear multiple different glycosylated viruses, such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), Dengue, West Nile, multiple strains of influenza, Ebola, Chikungunya, smallpox, monkeypox, multiple herpes viruses, a MERS-CoV related pseudovirus, and others. Hemopurifier is used as a device for two independent indications: the treatment of individuals with advanced or metastatic cancer and the treatment of life threating viruses that are not approved therapies.
More about the company
Last Close Price
1.36
USD
Average target price
25.05
USD
Spread / Average Target
+1,741.91%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1